GAIN THERAPEUTICS, INC Increase (Decrease) in Accounts Receivable
GAIN THERAPEUTICS, INC (GANX) reported Increase (Decrease) in Accounts Receivable of -$8.26 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-03-23
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for the quarter ending 2021-12-31 was -$24.43K, a 465.32% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was -$328.45K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for the quarter ending 2020-12-31 was $6.69K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for the quarter ending 2020-09-30 was -$107.22K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for fiscal 2021 was -$8.26K, a 4316.33% decline from fiscal 2020.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts receivable for fiscal 2020 was $196.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$24.43K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$352.88K derived: sum of 2 quarters · filed 2023-03-23 | -$8.26K 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$328.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $16.16K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $344.62K 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $6.69K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$100.53K derived: sum of 2 quarters · filed 2022-03-25 | $196.00 10-K · filed 2022-03-25 | |
| 2020-09-30 | -$107.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$6.49K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $100.73K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |